New Understandings of HR-MDS and AML: Linking Immune
Dysfunction to TIM-3 Expression



Connecting TIM-3 Expression to Immune Dysfunction in HR-MDS and AML

MDS Disease Complexity and Immune Dysfunction

The Novel Target TIM-3

Unmet Needs in Higher-Risk MDS

Expert Videos

Rami Komrokji, MD

Komrokji Video

Connecting TIM-3 Expression to Immune Dysfunction in HR-MDS and AML

Understanding the link between TIM-3 expression and immune dysfunction in HR-MDS and AML

David Steensma, MD

Steensma Video

MDS Disease Complexity and Immune Dysfunction

Gain a deeper understanding of the role that immune dysfunction plays in HR-MDS, including how it manifests differently, depending on disease severity

Uwe Platzbecker, MD

Platzbecker Video

The Novel Target TIM-3

Expand your knowledge of the role TIM-3 plays as a driver of immune dysfunction and leukemic stem cell proliferation in HR-MDS

Andrew Wei, MBBS, PhD

Wei Video

Unmet Needs in Higher-Risk MDS

Understand the key unmet needs in the HR-MDS space today, including poor prognosis and limited treatment options


Meet the Speakers

Speaker

Rami Komrokji, MD

Vice Chair of the Malignant
Hematology Department
Moffitt Cancer Center
Tampa, Florida
United States

Speaker

David Steensma, MD

Hematologist Oncologist
Novartis
Cambridge, Massachusetts
United States

Speaker

Uwe Platzbecker, MD

Hematologist Oncologist
University Hospital
Leipzig, Germany

Speaker

Andrew Wei, MBBS, PhD

Hematologist
Alfred Hospital
Melbourne, Australia

Novartis Pharma AG
© 2021 Novartis
11/21 169896
Novartis Pharmaceuticals Corporation
Novartis
Novartis Pharma AG

© 2021 Novartis

11/21

169896

Novartis Pharmaceuticals Corporation